Table 2.

Patient and disease characteristics at baseline

ENC + CTX, n = 26ENC + ALP + CTX, n = 28
Sex, n (%)
 Female15 (58)18 (64)
 Male11 (42)10 (36)
Age, median (range), years63 (43–80)59 (40–76)
Primary site of cancer derived, n (%)
 Colon24 (92)25 (89)
 Rectum2 (8)3 (11)
ECOG PS, n (%)
 08 (31)18 (64)
 116 (62)10 (36)
 22 (8)0
Visceral involvement at baseline, n (%)
 Liver15 (58)16 (57)
 Peritoneum5 (19)8 (29)
Lactate dehydrogenase levels at baseline, n (%)
 Normal9 (35)10 (36)
>Upper limit of normal15 (58)14 (50)
 Missing2 (8)4 (14)
Number of prior treatment regimens, n (%)
 17 (27)10 (36)
 28 (31)14 (50)
 35 (20)1 (4)
 >36 (23)3 (11)
Best response to last prior therapy, n (%)
 Partial response02 (7)
 Stable disease10 (39)12 (43)
Progressive disease9 (35)9 (32)
Unknown/not applicable7 (27)5 (18)
  • Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ENC + ALP + CTX, encorafenib combined with alpelisib and cetuximab; ENC + CTX, encorafenib combined with cetuximab.